Foundation Medicine Inc. is adding fully integrated and validated assessments of tumor mutational burden (TMB) and microsatellite instability (MSI) to its FoundationOne solid-tumor genomic test, and FoundationOne Heme hematologic and sarcoma molecular diagnostics systems to help oncologists identify the best therapies for their advanced-stage cancer patients.
The tests can easily be incorporated into the same genomic test report that FoundationOne and FoundationOne Heme already produce without requiring additional cost or time, according to Vince Miller, Foundation Medicine's chief medicine officer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?